150 results on '"Moyo, Tamara K."'
Search Results
2. Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
3. Splenomegaly Segmentation on Multi-modal MRI using Deep Convolutional Networks
4. SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth
5. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
6. The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
7. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study
8. Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy.
9. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
10. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib
11. Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline
12. Revisiting the role of autologous stem cell transplant in relapsed/ refractory aggressive B cell lymphoma
13. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
14. Supplementary File 1 from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
15. Data from PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
16. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis
17. Postibrutinib relapse outcomes for patients with marginal zone lymphoma
18. Therapy for Chronic Myelomonocytic Leukemia in a New Era
19. Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
20. Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
21. Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
22. Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
23. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes
24. Corrigendum to “Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline” [Comput. Biol. Med. 107 (2019) 109–117]
25. Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting- Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients
26. Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel
27. Platform Incorporating Patient Navigation, Preparative Guidelines, and Hospital at Home May Improve COVID-19 Outcomes for Patients with Myeloid Malignancies
28. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type
29. Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis
30. Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma
31. Outcomes in Patients with Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers
32. The delta isoform of PI3K predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib
33. A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
34. Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study
35. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type.
36. Late Psychiatric and Neurocognitive Effects of Chimeric Antigen Receptor T Cell Therapy Warrant Further Investigation
37. Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition
38. Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks
39. SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth
40. Improving splenomegaly segmentation by learning from heterogeneous multi-source labels
41. Improving Splenomegaly Segmentation by Learning from Heterogeneous Multi-Source Labels.
42. Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
43. Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma
44. Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant to Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Analysis from 14 U.S. Academic Centers
45. Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers
46. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
47. Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy
48. Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T-Cell (CART) Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)
49. Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities
50. Preliminary Results from a Phase 1b Dose De-Escalation Stage of Abnl-Marro 001: An International MDS/MPN Working Group Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.